05
Nov
2019

Share

Why we win when iRobot loses

Some time back, our Montaka global fund took a short position in iRobot (Nasdaq: IRBT), which makes Roomba robotic vacuum cleaners (RVCs).  So far, our strategy is paying off, with the IRBT share price collapsing over the past six months.

While these devices automate vacuuming, and provide reprieve from an otherwise monotonous task, there is mounting evidence that IRBT is following the path many pioneering companies of a new technology follow: one of commoditization, competition, and significant price deflation.

We are seeing clear evidence of competition biting, and increasing challenges being faced by the business. IRBT has had to increase promotional spending to combat intensifying competition from Chinese manufacturers of RVCs. Let’s look at an example. IRBT’s Roomba i7+ retails for around $1,000. This is IRBT’s flagship model, with all the bells and whistles, including automatic dirt disposal and home mapping. Now let’s consider the equivalent Shark IQ RVC, a Chinese competitor product. The Shark IQ RVC also includes self-emptying features and home mapping. The key difference is that the Chinese competitor RVC doesn’t cost $1,000 – it costs just $450.

It’s perhaps unsurprising that earlier this month IRBT sued SharkNinja Operating LLC, the company that manufactures the Shark IQ RVC, for patent infringement. IRBT’s complaint makes the following remark: “Shark is not even shy about being a copycat—claiming that the Shark IQ Robot offers the same iRobot technology at ’half the price of iRobot i7+’”.

This litigation case is symptomatic of a situation of rising competition, and competitor products that are quickly able to catch up to the features of IRBT’s Roomba RVCs. At a minimum this litigation case will require incremental costs from IRBT to pursue its patent infringement claims. In a worst-case scenario for IRBT, the company could receive an unfavorable ruling which would provide a clear path for competitors to compete away IRBT’s market share. We are already seeing evidence of this, with IRBT losing an estimated 10 percentage points in market share year-over-year in 2018.

Screen Shot 2019-11-04 at 4.36.37 pm

Source: Company filings, NPD, GfK, China Online; via Bank of America Merrill Lynch

 

IRBT until recently has had a clear first mover advantage, given that they pioneered the RVC category. However, as competition continues to increase and these RVCs become increasingly commoditized, the category is likely to experience price deflation. We have seen this dynamic with countless other new technologies such as radios, televisions and computers. We see no reason why the RVC category will be able to escape this fate. IRBT’s woes are being compounded by its exposure to tariffs that have been imposed on China, given that all of its RVCs are manufactured in China.

During the second quarter of 2019, in response to higher tariffs, IRBT raised prices on its products. Unlike the first round of price increases, IRBT’s Chinese competitors did not follow IRBT’s second round of price increases. The result was a capitulation by IRBT, following the poor customer response: “Sell-through following our late July price increases was suboptimal…we elected to roll back our pricing to pre-tariff levels on most of our products”. What follows over the next few quarters could be particularly interesting.

IRBT’s gross margin declined by 450 bps in Q2, and this was with the price increases in place to mitigate tariffs. We are likely to see further gross margin compression in future quarters, in addition to the top-line pressures being faced by the business. Despite the IRBT short having performed well for our investors, we continue to see further downside as pressures build in the coming quarters.

Screen Shot 2019-11-04 at 4.35.07 pm

Source: Bloomberg

Montaka own is short shares in iRobot. This article was prepared 04 November with the information we have today, and our view may change. It does not constitute formal advice or professional investment advice. If you wish to trade iRobot you should seek financial advice.

Our Funds

The Montgomery Fund

  • AUSTRALIA/NZ
  • Concentrated high conviction equities
  • From $25,000
Learn More

Montgomery Global Fund

  • GLOBAL
  • Concentrated high conviction equities
  • From $25,000
Learn More

Montgomery Alpha Plus Fund

  • GLOBAL
  • A market neutral strategy
  • From $50,000
Learn More

Montaka Global Access Fund

  • GLOBAL
  • Access long/short global equity portfolio
  • From $50,000
Learn More

Montgomery Global Equities Fund (ASX:MOGL)

  • GLOBAL
  • Concentrated high conviction equities
  • No minimum investment - see your broker limits
Learn More

Montgomery Small Companies Fund

  • AUSTRALIA/NZ
  • Concentrated high conviction equities
  • From $25,000
Learn More
Close

Our Funds

Concentrated High Conviction Equities

Listed

Montgomery Global Equities Fund (ASX:MOGL)

Global
Available on the ASX as an Exchange Traded Managed Fund, invests in 15 to 30 quality global businesses for long-term capital growth with a target distribution yield of 4.5% per annum. Mirrors the strategy of the Montgomery Global Fund.
Unlisted From $25,000

Montgomery Global Fund

Global
Invests in 15 to 30 quality global businesses for long-term capital growth. Priced daily. Mirrors the strategy of the Montgomery Global Equities Fund (ASX:MOGL).
Unlisted from $25,000

The Montgomery Fund

Australia/NZ
Aims to provide long-term growth and income by investing in 20 to 40 high-quality Australian and New Zealand businesses trading at attractive valuations. Priced daily.
New Fund

Montgomery Small Companies Fund

Australia/NZ
Aims to provide long-term growth by investing in 30 to 50 high quality, undervalued, Australian and NZ small and emerging companies with strong growth potential. Priced daily.
Unlisted from $1 Million

The Montgomery [Private] Fund

Australia/NZ
Seeks to deliver absolute returns from a portfolio of high-quality Australian and New Zealand businesses. Capital preservation is paramount. By invitation only.

Alternate Equity Strategies

Unlisted from $50,000

Montgomery Alpha Plus Fund

Global
Aims to generate positive returns in both rising and falling markets. Invests in 80 to 180 global businesses expected to deliver above-average returns, while selling short a similar-sized portfolio expected to deliver below-average returns. Priced daily.
Unlisted from $50,000

Montaka Global Access Fund

Global
Aims to generate materially higher risk-adjusted returns, net of fees, than is generally available in the equities market over the medium term. Priced monthly. Provides retail investors access to the Montaka Global Fund.
Unlisted From $1 Million

Montaka Global Fund

Global
Aims to generate materially higher risk-adjusted returns, net of fees, than is generally available in the equities market over the medium term. By invitation only.